Clinical trial
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
Opening soon · Phase 1 · 0 countries · Registry ID NCT07337174
Opening soonPhase 1Interventional
What this study is about
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age19 Years to 65 Years
SexAll
Healthy volunteersAccepted
ConditionObesity
Full registry criteria
Inclusion Criteria: * Healthy adult volunteers aged 19 to 65 years, inclusive, at screening. * Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period. Exclusion Criteria: * Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders. * For females: Pregnant women (positive urine hCG) or nursing mothers.
Treatments and study arms
HUC2-676
Drug
subcutaneous injection
HUC2-676-R
Drug
subcutaneous injection
Primary outcomes
Cmax following single-dose administration0 through 72 hours post-dose
AUC following single-dose administration0 through 72 hours post-dose
Study locations
0 locations were listed when this page was built. The first 40 are shown.
No public site location was included in this record. Check the original registry for updates.